Femasys (FEMY) vs SeaStar Medical (ICU)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
SeaStar Medical (ICU) has outperformed Femasys (FEMY) over the past year, losing 47.0% versus a loss of 82.9%. Over five years, FEMY leads with a -98.5% price change compared with -99.9% for ICU. SeaStar Medical is the larger company by market cap ($18.4 million vs $17.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FEMY | ICU |
|---|---|---|
| Share price | $2.05 | $3.49 |
| Market cap | $17.13M | $18.36M |
| 1-day change | +2.25% | -6.18% |
| YTD return | -82.25% | +45.42% |
| 1-year return | -82.87% | -47.04% |
| 5-year return | -98.54% | -99.86% |
| EPS (TTM) | $-3.28 | $-2.97 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $22.20 | $7.35 |
| 52-week low | $1.94 | $2.07 |
| Distance from 52-week high | -90.79% | -52.52% |
| Analyst consensus | none | none |
| Avg. price target upside | +600.73% | +186.53% |
| Average volume | 722.09K | 99.80K |
| Shares outstanding | 8.38M | 5.26M |
| Employees | 51 | 18 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ICU has outperformed FEMY by 35.8 percentage points over the past year.
About Femasys
FEMY stock →Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation.
Health Care · Medical/Dental Instruments · 51 employees
About SeaStar Medical
ICU stock →SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis.
Health Care · Medical/Dental Instruments · 18 employees
FEMY vs ICU FAQ
Which is bigger, Femasys or SeaStar Medical?
SeaStar Medical (ICU) is larger, with a market capitalization of $18.36M compared with $17.13M for Femasys (FEMY).
Which stock has performed better over the past year, FEMY or ICU?
ICU returned -47.04% over the past 12 months, compared with -82.87% for FEMY (price return, excluding dividends). Past performance does not predict future results.
Are Femasys and SeaStar Medical in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.